Century Therapeutics Inc


Century Therapeutics Inc

  • Price (USD)12.15
  • Today's Change1.00 / 8.97%
  • Shares traded97.40k
  • 1 Year change-61.31%
  • Beta--
Data delayed at least 15 minutes, as of Aug 12 2022 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing capabilities intended to minimize product development and supply risk. The Company's pipeline includes CNTY-101, CNTY-103, CNTY-102 and CNTY-104. The Company’s lead product candidate, CNTY-101, is focused on targeting B-cell lymphoma. CNTY-103 is designed to treat glioblastoma. CNTY-102 is designed to improve B-cell malignancy treatment. CNTY-104, is being developed to treat acute myeloid leukemia (AML). CAR design is a component of cell therapy product candidates. In addition to its programs, the Company is also actively engaged in a number of earlier stage discovery programs.

  • Revenue in USD (TTM)1.06m
  • Net income in USD-114.99m
  • Incorporated2018
  • Employees170.00
  • Location
    Century Therapeutics Inc3675 Market StPHILADELPHIA 19104United StatesUSA
  • Phone+1 (215) 981-4000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.centurytx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Somalogic Inc85.75m-82.04m723.69m320.00--1.27--9.14-0.4517-0.45170.47173.390.18033.514.66267,956.30-17.25---18.19--54.67---95.68--24.42--0.00--46.05---65.14------
Dice Therapeutics Inc1.13m-59.48m747.38m56.00--2.64--692.88-1.58-1.580.037.72------24,456.52-------------5,287.47------0.0082--30.36---106.24------
Nuvalent Inc0.00-57.10m751.28m48.00--3.14-----1.70-1.700.005.570.00----0.00-39.07---40.63--------------0.00-------218.34------
HeadHunter Group PLC294.20m84.43m761.05m1.36k9.2213.947.282.591.631.635.681.080.8629--147.61216,164.6025.1514.0741.4720.17----29.1524.38--16.580.704838.7392.8033.69208.22165.5214.19--
Century Therapeutics Inc1.06m-114.99m770.94m170.00--1.72--644.13-3.58-3.580.02376.710.0025----6,223.53-27.50---28.69-------10,868.53-----81.770.0253-------78.86------
Forrester Research, Inc.525.08m30.57m792.79m1.78k27.20--15.161.561.591.5927.21--------294,823.70--2.32--4.3758.8058.925.822.75--16.44--48.6910.108.68148.697.0821.02--
SP Plus Corp1.39bn46.50m806.29m10.80k16.613.3911.200.60712.182.1864.8110.651.26--10.45128,296.304.460.256.250.340415.0913.033.550.1932--4.850.5553--8.31-6.13118.346.53-10.59--
POINT Biopharma Global Inc0.00-56.50m808.42m72.00--3.39-----0.6264-0.62640.002.650.00----0.00-38.75---42.17-------------956.290.00-------243.25------
Viad Corp913.74m-30.14m812.89m3.51k----28.120.9388-1.48-1.4544.316.060.876266.2710.01260,175.10-1.48-6.64-2.05-9.744.402.30-1.69-6.920.96680.80390.6912--22.12-15.8972.69--3.07--
Relmada Therapeutics Inc0.00-143.28m817.25m10.00--4.09-----7.19-
Kelly Services, Inc.5.00bn81.70m831.41m7.40k10.950.66497.920.16952.042.04127.3133.601.85--3.57675,702.702.802.414.673.8519.2918.081.511.14----0.000214.078.72-1.43314.865.53-2.48--
Instil Bio Inc0.00-187.78m835.24m412.00--1.69-----1.46-1.460.003.940.00----0.00-29.78---31.12-------------147.270.00---100.00---315.48------
Data as of Aug 12 2022. Currency figures normalised to Century Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

30.30%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Jun 20227.33m12.45%
Casdin Capital LLCas of 31 Mar 20223.21m5.45%
BlackRock Fund Advisorsas of 30 Jun 20221.18m2.00%
Federated Global Investment Management Corp.as of 31 Mar 20221.16m1.98%
Deep Track Capital LPas of 30 Jun 2022924.64k1.57%
RA Capital Management LPas of 31 Mar 2022914.09k1.55%
The Vanguard Group, Inc.as of 30 Jun 2022891.40k1.52%
Avidity Partners Management LPas of 31 Mar 2022865.00k1.47%
Marshall Wace LLPas of 31 Mar 2022701.34k1.19%
Octagon Capital Advisors LPas of 31 Mar 2022658.27k1.12%
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.